155 related articles for article (PubMed ID: 32772613)
21. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
[TBL] [Abstract][Full Text] [Related]
22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
23. Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
Hogenhout R; Osses DF; Alberts AR; Buizer-Rijksen HG; Remmers S; Roobol MJ
BJU Int; 2023 May; 131(5):596-601. PubMed ID: 36408660
[TBL] [Abstract][Full Text] [Related]
24. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
25. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
26. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
27. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
[TBL] [Abstract][Full Text] [Related]
29. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7.
Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847
[TBL] [Abstract][Full Text] [Related]
31. Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort.
Elyan A; Saba K; Sigle A; Wetterauer C; Engesser C; Püschel H; Attianese S; Maurer P; Deckart A; Cathomas R; Strebel RT; Gratzke C; Seifert HH; Rentsch CA; Mortezavi A
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37813730
[TBL] [Abstract][Full Text] [Related]
32. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
33. Men's perception of information and psychological distress in the diagnostic phase of prostate cancer: a comparative mixed methods study.
Søndergaard MEJ; Lode K; Husebø SE; Dalen I; Kjosavik SR
BMC Nurs; 2022 Sep; 21(1):266. PubMed ID: 36180907
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
Nordström T; Akre O; Aly M; Grönberg H; Eklund M
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):57-63. PubMed ID: 29259293
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.
Yoneyama T; Tobisawa Y; Kaneko T; Kaya T; Hatakeyama S; Mori K; Sutoh Yoneyama M; Okubo T; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Ito A; Koie T; Suda Y; Gardiner RA; Ohyama C
Cancer Sci; 2019 Aug; 110(8):2573-2589. PubMed ID: 31145522
[TBL] [Abstract][Full Text] [Related]
36. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
37. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
[TBL] [Abstract][Full Text] [Related]
40. Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy.
Vėželis A; Platkevičius G; Kinčius M; Gumbys L; Naruševičiūtė I; Briedienė R; Petroška D; Ulys A; Jankevičius F
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
